Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Spanish police and soldiers track boars, reinforce farm security amid swine fever outbreak - 2How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
- 34 Dazzling And Well known Island Objections In US
- 4Germany's Merz under fire in Brazil for his comments on Amazon host city of COP30
- 5Ice Spice's 'Big Guy' SpongeBob song is stuck in everyone's heads again — and TikTok is fueling it
- Iran steps up executions as experts warn state killing being used to suppress political dissent
- 10 Fundamental Tips and Deceives to Lift Your Cell phone's Exhibition
- The most effective method to Explore Moral Situations in Brain research with Your Certification
- Step by step instructions to Think about Disc Rates Across Various Banks
- Florida has quietly become America's execution capital
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
- I decided to become a single mother by choice. I wasn't ready to stop dating.
- The Force of Positive Reasoning: Day to day Attestations
- Are IDF reservists properly armed during post-war operations?
